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pulmonary bypass (CPB). The x-axis shows the value for target ACT beforeDespite evidence-based guidelines for blood conservation in
cardiac surgery,1 the clinical management of anticoagula-
tion during cardiopulmonary bypass (CPB) is not standard-
ized. This is further complicated by the fact that patients’
responsiveness to heparin is variable. Impaired heparin re-
sponsiveness or ‘‘heparin resistance’’ is often the result of
patient-specific causes, such as antithrombin deficiency or
high concentrations of heparin-binding proteins, but can
also be due to the heparin formulation itself. In clinical
practice inhibiting thrombin formation/activity during CPB
is essential to minimizing overt thrombosis, the clinical
consequences of a consumptive coagulopathy, or both.
A survey of anticoagulation practices, published in 1999,2
observed significant variability in practice with reported ac-
ceptable activated clotting times (ACTs) ranging from 240 to
1000 seconds. The purpose of the present analysis a decade
later is to characterize current anticoagulation management
strategies for CPB.
instituting CPB, and the y-axis shows the percentage of sites reporting that
particular target value.CLINICAL SUMMARY
After institutional review board approval, an 18-question
written survey was distributed by e-mail to 162 academic
and nonacademic institutions in the United States and
Canada in 2008. The survey was conducted by the Duke
Clinical Research Institute (Durham, NC) and sponsored
by GTC Biotherapeutics, Inc (Framingham, Mass). Surveys
were sent to a cardiac surgeon or cardiac anesthesiologist at
each site, and respondents were asked to comment on current
practice. Summary data were calculated and are presented as
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Of the 162 surveys sent, responses were received from 54
(33%) sites. Forty-one of these institutions were located
within the United States, and 13 were located in Canada.
Overall, 43% (23/54) of sites performed 500 or fewer cases
with CPB annually, whereas 24% (13/54) of sites performed
more than 1000 cases with CPB annually.
For US respondents, 78% used empiric weight-based
dosing to guide the initial heparin dose compared with
100% of Canadian institutions, and 22% of US institutions
used an in vitro heparin dose-response method to determine
the initial heparin dose. The target ACT for instituting CPB
ranged from less than 350 seconds to 500 seconds (Figure 1).
However, a majority of institutions used a value of between
400 and 480 seconds (ie, 71% for US sites and 69% for Ca-
nadian sites). The maximum heparin dose administered to
achieve the target ACT before considering supplemental
therapies (eg, plasma or antithrombin concentrate) is shown
in Figure 2, with 57% of US and 77% of Canadian centers
using a value of 500 IU/kg or greater.diovascular Surgery c Volume 139, Number 6 1665
FIGURE 2. Maximum heparin dose before considering alternatives (fresh
frozen plasma or antithrombin concentrate). The x-axis shows the value for
total heparin dose in units per kilogram body weight before considering al-
ternatives, such as fresh frozen plasma or antithrombin concentrate, and the
y-axis shows the percentage of sites reporting a maximum total heparin
dose.
Brief Research ReportHeparin resistance was sometimes or always treated with
fresh frozen plasma in 85% of US sites. Heparin resistance
was sometimes or always treated with antithrombin concen-
trate in 46% of US sites surveyed. Canadian institutions used
mostly fresh frozen plasma (85%), and only 1 (8%) site used
antithrombin concentrate to treat heparin resistance.
In addition, for CABG surgery with CPB, 95% of US
sites used e-aminocaproic acid (EACA), but no Canadian
site surveyed used EACA. Only 7 (17%) US sites used tra-
nexamic acid in contrast to 100% of Canadian sites.
DISCUSSION
Despite several decades of cardiac surgery with heparin-
based anticoagulation for CPB, the target ACT that confers
a level of safe anticoagulation has not been universally
defined; however, an ACT that approximates 400 to 4801666 The Journal of Thoracic and Cardiovascular Surseconds is most commonly used. Our survey demonstrates
that there is still variability in the management of heparin-
based anticoagulation for CPB, yet there is even more vari-
ability in the diagnosis and management of heparin resistance.
Previous studies have shown that heparin resistance occurs in
a small percentage of patients. This low incidence might ex-
plain the paucity of literature aimed at assessing the optimal
therapy for this problem.3,4
It is also notable that most (95%) US centers use the
lysine analogue EACA, whereas Canadian centers exclu-
sively used tranexamic acid. The Blood Conservation Using
Antifibrinolytics in a Randomized Trial (BART) study dem-
onstrated no clear superiority of one lysine analogue over the
other.5 These differences in use are regional and might
reflect economic or political factors or variable interpretation
of the literature. All surveys have inherent limitations, in-
cluding selection bias and nonresponse bias. Despite a mod-
est response rate, we obtained survey data from a relatively
large number of sites, which increases the ability to general-
ize our findings.
In summary, our survey of 54 North American sites
reveals significant variability with respect to anticoagulation
practices. More studies are needed to determine whether this
variability in care is of clinical relevance.References
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